
Muscle, fat, nerve and other connective tissue.
This map explains soft tissue sarcoma step by step: what it is, the types, the tests, the stages, the treatment and its side effects.
Tap any topic on the map to read about it. Topics with an arrow open more topics.
The exact type matters for treatment. Tap a type on the map.
Mainly in children and young adults. Very sensitive to chemotherapy, which is the main treatment along with surgery or radiotherapy.
Tap a test on the map to see why it is done.
Please wait for all the reports. Why we wait
Done before any biopsy or surgery. Shows the size, depth and relation to nerves and vessels.
A needle biopsy, planned so that the needle track can be removed later with the tumour. The lump should not be simply cut out before a scan and biopsy, as this can make proper surgery harder.
Some types are confirmed by specific mutations (for example SS18 in synovial sarcoma, MDM2 in liposarcoma).
NGS (next-generation sequencing) reads many genes in the tumour at once. In sarcoma it helps in two ways: it can confirm the exact type, and it can find a mutation that a specific medicine can target.
| Sample | How it is done |
|---|---|
| Biopsy tissue | No new procedure is usually needed. RNA-based NGS is preferred, as it picks up the gene fusions that many sarcomas have. |
When is it advised? When the type is uncertain under the microscope, and in sarcoma that has spread or come back, before choosing the next treatment.
What the doctor is looking for:
| Finding | What it can mean |
|---|---|
| Gene fusions (SS18-SSX, EWSR1, FUS and others) | Confirm the type, for example synovial sarcoma or Ewing sarcoma, which changes the treatment plan. |
| MDM2 and CDK4 | Confirm well-differentiated or dedifferentiated liposarcoma. |
| NTRK fusion (rare) | Larotrectinib or entrectinib tablets, which work in most patients with this fusion. |
| ALK fusion | Inflammatory myofibroblastic tumour: crizotinib tablets. |
| TSC1 or TSC2 | PEComa: sirolimus-type medicines (nab-sirolimus). |
| BRAF V600E | BRAF and MEK tablets in selected patients. |
| MSI-high or TMB-high | Immunotherapy may work. |
CT chest checks the lungs. PET-CT or CT of the abdomen for some types.
Before starting chemotherapy, immunotherapy or targeted therapy, these tests check that you are fit for treatment, and give a starting point to compare with later.
| Test | Why it is done |
|---|---|
| CBC (complete blood count) | Haemoglobin, white cells and platelets. Treatment can lower them. |
| RFT (kidney function) | Many medicines are cleared by the kidneys; the dose may need to change. |
| LFT (liver function) | Many medicines are processed by the liver. |
| Viral markers: HBsAg, anti-HCV, HIV | Hepatitis B can flare up during treatment. If positive, a tablet is given to prevent this. |
| Blood sugar (and HbA1c if diabetic) | Steroids given with chemotherapy can raise blood sugar. |
| ECG and 2D Echo | Check the heart rhythm and pumping before treatment, as some medicines affect the heart. |
Before immunotherapy, also:
| Test | Why it is done |
|---|---|
| Serum TSH (thyroid) | Immunotherapy can affect the thyroid gland. |
| Serum cortisol (morning sample) | Immunotherapy can affect the adrenal and pituitary glands. |
Sometimes needed, depending on your treatment:
Your doctor will choose the tests that apply to you. Some of them are repeated during treatment.
Sarcoma stage depends on the grade, size, depth and spread. Tap your stage on the map.
Slow growing, limited to one area. Usually cured with surgery.
Faster growing, limited to one area. Cure is likely with surgery and radiotherapy, sometimes chemotherapy.
Spread to the lungs or elsewhere. Treatment aims to control it; some with a few lung deposits can still be cured with surgery.
Tap your stage on the map.
Side effects: surgery · radiotherapy · chemotherapy
Side effects: chemotherapy · pazopanib
Tap a treatment on the map.
Fever of 38°C or more during chemotherapy, new breathlessness or cough, a red or discharging wound, or blood in the urine (with ifosfamide) need urgent care.
This information is general. Your own treatment plan may be different. Please discuss it with your doctor.
Written and medically reviewed by Dr Prathyusha Eaga, MD, DM (Medical Oncology). Last reviewed: 12 October 2026. Based on NCCN and ESMO guidelines.
Book a hospital visit, a video consultation or a second opinion.